Communication Of Fidaxomicin's 30-Day Effect Is Question For Labeling Discussions
• By The Pink Sheet Daily
Anti-Infective Drugs Advisory Committee votes 13-0 to approve the antibiotic for treating Clostridium difficile, but rejects a claim for lowering the risk of recurrence, preferring focus on effect at 30 days.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
